Biomedical Engineering Reference
In-Depth Information
49. Zhu C-Q, da Cunha Santos G, Ding K,
Role of KRAS and EGFR as
biomarkers for response to erlotinib in National Cancer Institute of
Canada Clinical Trials Group study BR21.
et al.
JCO
26, 4268-4275 (2008).
50. Hirsch FR, Varella-Garcia M, Bunn Jr PA,
Molecular predictors
of outcome with gefitinib in a phase III placebo-controlled study in
advanced non-small-cell lung cancer.
et al.
JCO
24, 5034-5042 (2006).
51. Kim ES, Hirsh V, Mok T,
Gefitinib versus docetaxel in previously
treated non-small-cell lung cancer (INTEREST): a randomised phase
III trial.
et al.
372, 1809-1818 (2008).
52. Niho S, Ichinose Y, Tamura T,
Lancet
Results of a randomized phase III
study to compare the overall survival of gefitinib versus docetaxel in
Japanese patients with non-small cell lung cancer who failed one or
two chemotherapy regimens.
et al.
25, 387s [abstract] (2007).
=data&communityId=re753001&id=static/attachedfile/re7300002/
re77300002/AttachedFile_09853.pdf.
looking-at-erlotinib-after-treatment-for-non-small-cell-lung-cancer.
55. Hirsch FR, Varella-Garcia M, Cappuzzo F,
JCO
Combination of EGFR
gene copy number and protein expression predicts outcome for
advanced non-small-cell l ung cancer patients treated with gefitinib.
Ann Oncol
et al.
18, 752-760 (2007).
56. Lynch TJ, Patel T, Dreisbach L,
Cetuximab and first-line taxane/
carboplatin chemotherapy in advanced non-small-cell lung cancer:
results of the randomized multicenter phase III trial BMS099.
et al.
JCO
28,
911-917 (2010).
57. Khambata-Ford S, Harbison CT, Hart LL,
Analysis of potential
predictive markers of cetuximab benefit in BMS099, a phase III study
of cetuximab and first-line taxane/carboplatin in advanced non-small-
cell lung cancer.
et al.
28, 918-27 (2010).
58. Hirsch FR, Herbst RS, Olsen C,
JCO
Increased EGFR gene copy number
detected by fluorescent in situ hybridization predicts outcome in
non-small-cell lung cancer patients treated with cetuximab and
chemotherapy.
et al.
26, 3351-3357 (2008).
59. Hirsch FR, Franklin WA, Veve R,
JCO
et al.
HER2/neu expression in
29, 51-58 (2002).
60. Cappuzzo F, Varella-Garcia M, Shigematsu H,
malignant lung tumors.
Semin Oncol
Increased HER2
gene copy number is associated with response to gefitinib therapy in
epidermal growth factor receptor-positive non-small cell lung cancer
patients.
et al.
JCO
23, 5007-5018 (2005).
